Oxurion Competitors and Similar CompaniesClear all
Aerie Pharmaceuticals's competitors and similar companies include Alnylam.
 Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2005 | Founding Date 2002 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | |
Employees | Employees 3808% increase | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 722.2 m | Valuation ($) 36.5 b |
Financial | ||
Revenue (est.) | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $3.7b (FY, 2025) |
Cost of goods | Cost of goods $26.8m (FY, 2021) | Cost of goods $677.2m (FY, 2025) |
Net income | Net income ($74.8m) (FY, 2021) | Net income $313.7m (FY, 2025) |
Funding | ||
Total funding raised | Total funding raised $ 388.6m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company